TSH Biopharm Corp. Ltd.

As of June 30, 2026, TSH Biopharm Corp. Ltd. carries a market capitalization of 1.95B, placing it among publicly traded companies globally. Its enterprise value stands at 1.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

TSH Biopharm Corp. Ltd.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, TSH Biopharm Corp. Ltd. has 38.40M shares outstanding.

As of June 30, 2026, TSH Biopharm Corp. Ltd. trades at a trailing price-to-earnings ratio of 14.54. The price-to-sales ratio is 1.57, and the price-to-book ratio stands at 1.38.

As of June 30, 2026, TSH Biopharm Corp. Ltd. trades at an EV/EBITDA multiple of 4.74 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.93 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.34 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. TSH Biopharm Corp. Ltd. trades at an EV/FCF ratio of 4.08, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.16B versus a market cap of 1.95B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, TSH Biopharm Corp. Ltd. maintains a current ratio of 4.33, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.94, indicating moderate leverage, while an interest coverage ratio of 300.89 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, TSH Biopharm Corp. Ltd. posted a return on equity (ROE) of 9.55, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.36 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.90, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.97, useful for judging operating efficiency across full business cycles. The company generates approximately 17.15M in revenue per employee across its workforce of 72.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.49 indicates how many times TSH Biopharm Corp. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, TSH Biopharm Corp. Ltd. recorded 59.93M in income tax expense. That works out to an effective tax rate of 26.13, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 229.36M, leaving 134.61M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, TSH Biopharm Corp. Ltd.'s stock has declined approximately 1.26% over the past 52 weeks. The 50-day moving average sits at 51.44, while the 200-day moving average is 52.17.

Over the twelve months ended June 30, 2026, TSH Biopharm Corp. Ltd. generated 1.24B in revenue and converted that into 134.61M in net income, yielding earnings per share of 4.40. EBITDA reached 244.92M, while operating income came in at 215.37M.

As of June 30, 2026, TSH Biopharm Corp. Ltd. holds 1.07B in cash and equivalents against 15.80M in total debt, resulting in a net debt position of -618.00M. Total book value stands at 1.41B, with working capital of 1.14B providing operational flexibility.

TSH Biopharm Corp. Ltd. produced 292.80M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9.18M in capital expenditures, free cash flow totaled 283.62M - equivalent to 7.37 per share.

Over the twelve months ended June 30, 2026, TSH Biopharm Corp. Ltd. posted a gross margin of 53.75, reflecting its pricing power and cost economics. The operating margin of 17.32 and net profit margin of 10.83 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, TSH Biopharm Corp. Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 14.47, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.54, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to TSH Biopharm Corp. Ltd. shareholders.

TSH Biopharm Corp. Ltd.'s most recent stock split took place on August 28, 2013 with a 10:11 split ratio.

As of June 30, 2026, TSH Biopharm Corp. Ltd. has an Altman Z-Score of 5.59, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.